Title:NLRP3: A Promising Therapeutic Target for Inflammatory Bowel Disease
Volume: 24
Issue: 14
Author(s): Jiayu Zhang, Shuyan Zeng, Peng Wang, Youxiang Chen and Chunyan Zeng*
Affiliation:
- Department of Gastroenterology, Digestive Disease Hospital, the First Affiliated Hospital of Nanchang University,
Nanchang, China
- Huankui Academy of Nanchang University, Nanchang, China
Keywords:
Inflammatory bowel disease, NLRP3, inflammation, regulation, drugs, pro-inflammatory cytokines.
Abstract: Inflammatory bowel disease (IBD), which includes Crohn's disease and ulcerative colitis,
is an intestinal disease with complicated pathological mechanisms. The incidence of IBD has
been increasing in recent years, which has a significant negative impact on the lives of patients.
Therefore, it is particularly important to find new therapeutic targets and innovative drugs for the
development of IBD. Recent studies have revealed that NLRP3 inflammatory vesicles can play an
important role in maintaining intestinal homeostasis and sustaining the intestinal immune response
in IBD. On the one hand, aberrant activation of NLRP3 inflammatory vesicles may cause excessive
immune response by converting caspase-1, proIL-18, and proIL-1β to their active forms and
releasing pro-inflammatory cytokines to stimulate the development and progression of IBD, and
we can improve IBD by targeting blockade of NLRP3 activation. On the other hand, NLRP3 may
also play an enter protective role by maintaining the homeostasis of the intestinal immune system.
In this paper, we reviewed the activation mechanism of NLRP3 inflammasome, and the effects of
NLRP3 inflammasome activation on IBD are discussed from two different perspectives: pathology
and protection. At the same time, we listed the effects of direct inhibitors, indirect inhibitors,
and natural inhibitors of NLRP3 inflammasome on IBD in combination with cutting-edge advances
and clinical practice results, providing new targets and new ideas for the clinical treatment
of IBD.
